{"id":"W3167655766","doi":"10.1200/jco.2021.39.15_suppl.tps5607","title":"Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kelowna General Hospital","funders":"Mersana Therapeutics","keywords":"Medicine; Ovarian cancer; Oncology; Internal medicine; Cohort; Bevacizumab; Cancer; Olaparib; Fallopian tube cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002772837,0.001173363,0.001157777,0.0003523252,0.0005242692,0.001391145,0.0009449966,0.001295548,0.006896672],"category_scores_gemma":[0.001387801,0.000428701,0.001350889,0.0003361085,0.0005148234,0.0008142476,0.0008643253,0.002821547,0.002687257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001482744,"about_ca_system_score_gemma":0.002126597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002234934,"about_ca_topic_score_gemma":0.005997208,"domain_scores_codex":[0.9994648,0.0001752423,0.00002262182,0.00009901482,0.00009289579,0.0001454118],"domain_scores_gemma":[0.9990764,0.00008450617,0.0001375248,0.0000622747,0.000115634,0.0005236153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.3228411,0.02273692,0.04536071,0.002396868,0.002627527,0.001981373,0.000591572,0.003105486,0.06353257,0.004142209,0.1647587,0.3659251],"study_design_scores_gemma":[0.3990653,0.2454468,0.07659955,0.000900413,0.003150916,0.006431732,0.0004318186,0.004057413,0.01943217,0.004004002,0.2403062,0.0001737189],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8929343,0.02021565,0.003387057,0.009660838,0.001111523,0.008924571,0.04185476,0.0003985932,0.02151271],"genre_scores_gemma":[0.8448818,0.010034,0.009745997,0.01526355,0.0008435319,0.008517165,0.08968971,0.0004069973,0.02061734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006896672,"threshold_uncertainty_score":0.02307165,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08863282984229492,"score_gpt":0.4842604555080846,"score_spread":0.3956276256657897,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}